心血管风险是血阿尔茨海默病生物标志物与认知状态之间的关系的调节者
Angelina K Kancheva1, Donald M Lyall2, Kamen A Tsvetanov3,4
1School of Cardiovascular & Metabolic Health University of Glasgow Glasgow UK.
Journal of the American Heart Association
|December 30, 2025
概括
心血管风险影响阿尔茨海默氏症
科学领域:
- 神经学 神经学
- 生物标志物 生物标志物
- 心血管健康 心血管健康
背景情况:
- 血生物标志物显示出阿尔茨海默病 (AD) 诊断和预后的前景.
- 心血管风险与阿尔茨海默病的认知能力下降有关.
- 心血管风险对血生物标志物-认知状态关系的缓解作用在大型队列中尚未得到充分探索.
研究的目的:
- 在一个大型的多站点研究中,调查心血管风险是否能缓和血AD生物标志物与认知状态之间的关联.
主要方法:
- 包括745名参与者 (认知正常,轻度认知障碍或可能的AD).
- 使用动脉样硬化心血管疾病风险计算器量化心血管风险.
- 分析了心血管风险和血生物标志物 (Aβ42/40,p-tau181,p-tau217,apoE4) 与认知状态的关联,使用后勤回归,测试适度.
主要成果:
- 血生物标志物和心血管风险与认知状态独立相关.
- 酸化的tau-217 (p-tau217) 显示出与认知状态的最强相关性 (OR, 2.33).
- 心血管风险显著缓解了p-tau181和p-tau217与认知状态之间的关系 (P<0.05).
结论:
- 血AD生物标志物和心血管风险独立地与认知状态相关.
- 心血管风险改变了p-tau181和p-tau217与认知状态的关联.
- 心血管风险评估可以作为痴呆风险认知查中的血生物标志物评估的补充.
相关概念视频
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Atherosclerosis III: Management
290
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
290
Coronary Artery Disease I: Introduction
843
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
843
Alzheimer's Disease: Treatment
736
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
736


